Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-103 (polaprezinc) Phase III trial in patients with taste disorder
jRCT2080221862Phase 3
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Jul 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in Gustatory Dysfunction comparing Z-103 (polaprezinc) with Placebo (2 arms).
02
Drugs
polaprezinc
03
Conditions
Gustatory Dysfunction
Beyond the preview
Go deeper on jRCT2080221862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221862.